Yong Zhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yong Zhan has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Hailong An
Key Laboratory of Molecular Biophysics of Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, 300401, Tianjin, PR China
19 shared publications Yafei Chen
Key Laboratory of Molecular Biophysics, Hebei Province, Institute of Biophysics, School of Sciences, Hebei University of Technology, Tianjin 300401, China
13 shared publicationsHailin Zhang
Department of Pharmacology, Hebei Medical University, Shijiazhuang 050017, China
9 shared publicationsChunli Pang
Key Laboratory of Molecular Biophysics, Institute of Biophysics, School of Sciences, Hebei University of Technology, Tianjin, China
7 shared publicationsShuai Guo
State Key Laboratory of Reliability and Intelligence of Electrical Equipment, Hebei University of Technology, Tianjin 300130, China; Key Laboratory of Electromagnetic Field and Electrical Apparatus Reliability of Hebei Province, Hebei University of Technology, Tianjin 300130, China; Key Laboratory of Molecular Biophysics, Hebei Province, Institute of Biophysics, School of Sciences, Hebei University of Technology, Tianjin 300401, China
6 shared publications- Xuzhao Wang
State Key Laboratory of Reliability and Intelligence of Electrical Equipment, School of Electrical Engineering, Hebei University of Technology, Tianjin, China
6 shared publications
Latest Publications
- 8 February 2023
- Published by IOP Publishing in Chinese Physics B
- Vol. 32 (5) , 050504
Study on conversion of microstates in breast cell ensemble at the gene level based on the eigen-microstate method
Breast cancer is a malignant disease that seriously threatens women’s health. Studying the mechanism of cancer occurrence and development is an urgent problem to be solved. In this paper, the eigen-microstate method was used to study conversion of normal breast cells into breast cancer cells and the reason. The main conclusions are as follows: the microstates of normal breast cell and breast cancer cell are different. There is a state conversion when a normal breast cell transforms into a breast cancer cell. The main reason for this state conversion is the combined effect of tumor suppressor genes and oncogenes. By analyzing the function of key genes, it was found that these genes do play an important role in the development of breast cancer. The findings contribute to understanding the mechanism by which breast cancer occurs and progresses, and key genes can serve as potential biomarkers or target genes for breast cancer treatment.
- 8 February 2023
- Published by IOP Publishing in Chinese Physics B
- Vol. 32 (5) , 050504
Study on conversion of microstates in breast cell ensemble at the gene level based on the eigen-microstate method
Breast cancer is a malignant disease that seriously threatens women’s health. Studying the mechanism of cancer occurrence and development is an urgent problem to be solved. In this paper, the eigen-microstate method was used to study conversion of normal breast cells into breast cancer cells and the reason. The main conclusions are as follows: the microstates of normal breast cell and breast cancer cell are different. There is a state conversion when a normal breast cell transforms into a breast cancer cell. The main reason for this state conversion is the combined effect of tumor suppressor genes and oncogenes. By analyzing the function of key genes, it was found that these genes do play an important role in the development of breast cancer. The findings contribute to understanding the mechanism by which breast cancer occurs and progresses, and key genes can serve as potential biomarkers or target genes for breast cancer treatment.
- 1 August 2020
- Published by Elsevier in Biochemical Pharmacology
- Vol. 178, 114062
TMEM16A-inhibitor loaded pH-responsive nanoparticles: A novel dual-targeting antitumor therapy for lung adenocarcinoma
- 1 August 2020
- Published by Elsevier in Biochemical Pharmacology
- Vol. 178, 114062
TMEM16A-inhibitor loaded pH-responsive nanoparticles: A novel dual-targeting antitumor therapy for lung adenocarcinoma
- 1 May 2020
- Published by Elsevier in Pharmacological Research
- Vol. 155, 104721
Arctigenin, a novel TMEM16A inhibitor for lung adenocarcinoma therapy
- 1 May 2020
- Published by Elsevier in Pharmacological Research
- Vol. 155, 104721
Arctigenin, a novel TMEM16A inhibitor for lung adenocarcinoma therapy
- 1 January 2020
- Published by Elsevier in Biophysical Journal
- Vol. 118 (1) , 262-272
The Molecular Mechanism of Ginsenoside Analogs Activating TMEM16A
- 1 January 2020
- Published by Elsevier in Biophysical Journal
- Vol. 118 (1) , 262-272
The Molecular Mechanism of Ginsenoside Analogs Activating TMEM16A
- 1 September 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 517 (3) , 445-451
A novel anti-cancer mechanism of Nutlin-3 through downregulation of Eag1 channel and PI3K/AKT pathway
- 1 September 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 517 (3) , 445-451
A novel anti-cancer mechanism of Nutlin-3 through downregulation of Eag1 channel and PI3K/AKT pathway
- 28 October 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (6) , 8698-8708
Matrine is a novel inhibitor of the TMEM16A chloride channel with antilung adenocarcinoma effects
Calcium‐activated chloride channels (CaCCs) are ion channels with key roles in physiological processes. They are abnormally expressed in various cancers, including esophageal squamous cell cancer, head and neck squamous cell carcinoma, colorectal cancer, and gastrointestinal stromal tumors. The CaCC component TMEM16A/ANO1 was recently shown to be overexpressed in lung adenocarcinoma cells and may serve as a tumorigenic protein. In this study, we determined that matrine is a potent TMEM16A inhibitor that exerts anti‐lung adenocarcinoma effects. Patch clamp experiments showed that matrine inhibited TMEM16A current in a concentration‐dependent manner with an IC 50 of 27.94 ± 4.78 μM. Molecular simulation and site‐directed mutation experiments demonstrated that the matrine‐sensitive sites of the TMEM16A channel involve the amino acids Y355, F411, and F415. Results of cell viability and wound healing assays showed that matrine significantly inhibited the proliferation and migration of LA795 cells, which exhibit high TMEM16A expression. In contrast, matrine has only weak inhibitory effect on CCD‐19Lu and HeLa cells lacking TMEM16A expression. Matrine‐induced effects on the proliferation and migration of LA795 cells were abrogated upon shRNA‐mediated TMEM16A knockdown in LA795 cells. Finally, in vivo experiments demonstrated that matrine dramatically inhibited the growth of lung adenocarcinoma xenograft tumors in mice but did not affect mouse body weight. Collectively, these data indicate that matrine is an effective and safe TMEM16A inhibitor and that TMEM16A is the target of matrine anti‐lung adenocarcinoma activity. These findings provide new insight for the development of novel treatments for lung adenocarcinoma.
- 28 October 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (6) , 8698-8708
Matrine is a novel inhibitor of the TMEM16A chloride channel with antilung adenocarcinoma effects
Calcium‐activated chloride channels (CaCCs) are ion channels with key roles in physiological processes. They are abnormally expressed in various cancers, including esophageal squamous cell cancer, head and neck squamous cell carcinoma, colorectal cancer, and gastrointestinal stromal tumors. The CaCC component TMEM16A/ANO1 was recently shown to be overexpressed in lung adenocarcinoma cells and may serve as a tumorigenic protein. In this study, we determined that matrine is a potent TMEM16A inhibitor that exerts anti‐lung adenocarcinoma effects. Patch clamp experiments showed that matrine inhibited TMEM16A current in a concentration‐dependent manner with an IC 50 of 27.94 ± 4.78 μM. Molecular simulation and site‐directed mutation experiments demonstrated that the matrine‐sensitive sites of the TMEM16A channel involve the amino acids Y355, F411, and F415. Results of cell viability and wound healing assays showed that matrine significantly inhibited the proliferation and migration of LA795 cells, which exhibit high TMEM16A expression. In contrast, matrine has only weak inhibitory effect on CCD‐19Lu and HeLa cells lacking TMEM16A expression. Matrine‐induced effects on the proliferation and migration of LA795 cells were abrogated upon shRNA‐mediated TMEM16A knockdown in LA795 cells. Finally, in vivo experiments demonstrated that matrine dramatically inhibited the growth of lung adenocarcinoma xenograft tumors in mice but did not affect mouse body weight. Collectively, these data indicate that matrine is an effective and safe TMEM16A inhibitor and that TMEM16A is the target of matrine anti‐lung adenocarcinoma activity. These findings provide new insight for the development of novel treatments for lung adenocarcinoma.
- 26 October 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (5) , 7161-7173
Tetrandrine, a novel inhibitor of ether‐à‐go‐go‐1 (Eag1), targeted to cervical cancer development
Mortality‐to‐incidence ratios in patients with cancer are extremely high, positioning cancer as a major cause of death worldwide. Ether‐à‐go‐go‐1 (Eag1) is an ion channel that plays important roles in tumour proliferation, malignant transformation, invasion, metastasis, recurrence, and prognosis. Therefore, identifying potent and specific Eag1 channel inhibitors is crucial. In this study, we identified the first natural inhibitor of Eag1, the traditional Chinese medicine agent tetrandrine, and explored the underlying mechanism. Tetrandrine directly interacted with Eag1 and inhibited the currents in a concentration‐dependent manner (IC50 of 69.97 ± 5.2 μM), and the amino acids Ile 550, Thr 552, and Gln 557 in the Eag1 C‐linker domain were critical for tetrandrine’s inhibitory effect. Moreover, tetrandrine reduced the proliferation of HeLa cells and Chinese hamster ovary (CHO) cells stably expressing Eag1 in a concentration‐dependent manner. Finally, tetrandrine (30 mg/kg/day) inhibited tumor growth in mice, demonstrating a 64.21% inhibitory rate of HeLa cell‐transplanted tumors. These results suggest that tetrandrine is a potent and selective Eag1 channel inhibitor, and could act as a leading compound in the development of therapies for Eag1 ion channel dysfunction‐induced diseases.
- 26 October 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (5) , 7161-7173
Tetrandrine, a novel inhibitor of ether‐à‐go‐go‐1 (Eag1), targeted to cervical cancer development
Mortality‐to‐incidence ratios in patients with cancer are extremely high, positioning cancer as a major cause of death worldwide. Ether‐à‐go‐go‐1 (Eag1) is an ion channel that plays important roles in tumour proliferation, malignant transformation, invasion, metastasis, recurrence, and prognosis. Therefore, identifying potent and specific Eag1 channel inhibitors is crucial. In this study, we identified the first natural inhibitor of Eag1, the traditional Chinese medicine agent tetrandrine, and explored the underlying mechanism. Tetrandrine directly interacted with Eag1 and inhibited the currents in a concentration‐dependent manner (IC50 of 69.97 ± 5.2 μM), and the amino acids Ile 550, Thr 552, and Gln 557 in the Eag1 C‐linker domain were critical for tetrandrine’s inhibitory effect. Moreover, tetrandrine reduced the proliferation of HeLa cells and Chinese hamster ovary (CHO) cells stably expressing Eag1 in a concentration‐dependent manner. Finally, tetrandrine (30 mg/kg/day) inhibited tumor growth in mice, demonstrating a 64.21% inhibitory rate of HeLa cell‐transplanted tumors. These results suggest that tetrandrine is a potent and selective Eag1 channel inhibitor, and could act as a leading compound in the development of therapies for Eag1 ion channel dysfunction‐induced diseases.
- 1 April 2018
- Published by IOP Publishing in Chinese Physics Letters
- Vol. 35 (4)
A Dynamic Model of Heavy Ion 7 Li Irradiation Mutagenesis Based on Maize Inbred Line Nutrition Difference
- 1 April 2018
- Published by IOP Publishing in Chinese Physics Letters
- Vol. 35 (4)
A Dynamic Model of Heavy Ion 7 Li Irradiation Mutagenesis Based on Maize Inbred Line Nutrition Difference
- Open Access
- 27 September 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0182067
Allosteric-activation mechanism of BK channel gating ring triggered by calcium ions
Calcium ions bind at the gating ring which triggers the gating of BK channels. However, the allosteric mechanism by which Ca2+ regulates the gating of BK channels remains obscure. Here, we applied Molecular Dynamics (MD) and Targeted MD to the integrated gating ring of BK channels, and achieved the transition from the closed state to a half-open state. Our date show that the distances of the diagonal subunits increase from 41.0 Å at closed state to 45.7Å or 46.4 Å at a half-open state. It is the rotatory motion and flower-opening like motion of the gating rings which are thought to pull the bundle crossing gate to open ultimately. Compared with the ‘Ca2+ bowl’ at RCK2, the RCK1 Ca2+ sites make more contribution to opening the channel. The allosteric motions of the gating ring are regulated by three group of interactions. The first weakened group is thought to stabilize the close state; the second strengthened group is thought to stabilize the open state; the third group thought to lead AC region forming the CTD pore to coordinated motion, which exquisitely regulates the conformational changes during the opening of BK channels by Ca2+.
- 27 September 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9) , e0182067
Open AccessAllosteric-activation mechanism of BK channel gating ring triggered by calcium ions
Calcium ions bind at the gating ring which triggers the gating of BK channels. However, the allosteric mechanism by which Ca2+ regulates the gating of BK channels remains obscure. Here, we applied Molecular Dynamics (MD) and Targeted MD to the integrated gating ring of BK channels, and achieved the transition from the closed state to a half-open state. Our date show that the distances of the diagonal subunits increase from 41.0 Å at closed state to 45.7Å or 46.4 Å at a half-open state. It is the rotatory motion and flower-opening like motion of the gating rings which are thought to pull the bundle crossing gate to open ultimately. Compared with the ‘Ca2+ bowl’ at RCK2, the RCK1 Ca2+ sites make more contribution to opening the channel. The allosteric motions of the gating ring are regulated by three group of interactions. The first weakened group is thought to stabilize the close state; the second strengthened group is thought to stabilize the open state; the third group thought to lead AC region forming the CTD pore to coordinated motion, which exquisitely regulates the conformational changes during the opening of BK channels by Ca2+.
- 29 August 2017
- Published by Springer Nature in The Journal of Membrane Biology
- Vol. 250 (5) , 483-492
Identification of Resveratrol, an Herbal Compound, as an Activator of the Calcium-Activated Chloride Channel, TMEM16A
Calcium-activated chloride channels (CaCCs) play vital roles in a variety of physiological processes. Dysfunction of the CaCCs is implicated in many diseases. Drug discovery targeting at CaCCs has recently become possible with the determination that TMEM16A is the molecular identity of CaCCs. In this study, we demonstrated that resveratrol (RES), a Chinese traditional medicine compound, is a novel activator of TMEM16A. The yellow fluorescence protein quenching assay and measurement of intracellular calcium fluorescence intensity show that RES activates TMEM16A channels in an intracellular Ca2+-independent way. The data of inside-out patch clamp revealed that RES dose-dependently activates TMEM16A (EC50 = 47.92 ± 9.35 μM). Furthermore, RES enhanced the contractions of the ileum of guinea pigs by activating the TMEM16A channel, which indicated that RES might be a promising drug for the treatment of gastrointestinal hypomotility. As RES was able to induce TMEM16A channel activation, TMEM16A can be added to the list of RES drug targets.
- 29 August 2017
- Published by Springer Nature in The Journal of Membrane Biology
- Vol. 250 (5) , 483-492
Identification of Resveratrol, an Herbal Compound, as an Activator of the Calcium-Activated Chloride Channel, TMEM16A
Calcium-activated chloride channels (CaCCs) play vital roles in a variety of physiological processes. Dysfunction of the CaCCs is implicated in many diseases. Drug discovery targeting at CaCCs has recently become possible with the determination that TMEM16A is the molecular identity of CaCCs. In this study, we demonstrated that resveratrol (RES), a Chinese traditional medicine compound, is a novel activator of TMEM16A. The yellow fluorescence protein quenching assay and measurement of intracellular calcium fluorescence intensity show that RES activates TMEM16A channels in an intracellular Ca2+-independent way. The data of inside-out patch clamp revealed that RES dose-dependently activates TMEM16A (EC50 = 47.92 ± 9.35 μM). Furthermore, RES enhanced the contractions of the ileum of guinea pigs by activating the TMEM16A channel, which indicated that RES might be a promising drug for the treatment of gastrointestinal hypomotility. As RES was able to induce TMEM16A channel activation, TMEM16A can be added to the list of RES drug targets.